Pfizer: EU approves new type of lung cancer drug
(CercleFinance.com) - European regulators have approved Pfizer's biomarker-driven drug Lorviqua for patients with ALK-positive non-small cell lung cancer.
The European Commission has granted conditional marketing authorisation for Lorviqua as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALK-positive advanced non-small cell lung cancer.
The drug has been specifically developed to penetrate the blood brain barrier, Pfizer said.
Under the terms of the conditional approval, Pfizer will have to provide additional data from post-marketing studies, including from an ongoing Phase 3 trial.
Lorviqua is Pfizer's second lung cancer medication approved in Europe within two months and its third biomarker-driven medicine for lung cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The European Commission has granted conditional marketing authorisation for Lorviqua as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALK-positive advanced non-small cell lung cancer.
The drug has been specifically developed to penetrate the blood brain barrier, Pfizer said.
Under the terms of the conditional approval, Pfizer will have to provide additional data from post-marketing studies, including from an ongoing Phase 3 trial.
Lorviqua is Pfizer's second lung cancer medication approved in Europe within two months and its third biomarker-driven medicine for lung cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.